logo-loader
viewSkinBioTherapeutics PLC

SkinBioTherapeutics inks commercial deal with FTSE 100 chemical firm Croda

SkinBioTherapeutics PLC's (LON:SBTX) CEO Stuart Ashman speaks to Proactive London's Andrew Scott after announcing they've inked a commercial agreement for its skincare product with FTSE 100 speciality chemical company Croda International Plc (LON:CRDA).

Ashman says it's a significant first deal for them and provides third-party validation of its technology.

Quick facts: SkinBioTherapeutics PLC

Price: 30.99 GBX

AIM:SBTX
Market: AIM
Market Cap: £48.31 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Skinbiotherapeutics get set for live data trial to target skin conditions...

SkinBioTherapeutics PLC's (LON:SBTX) Stuart Ashman talks to Proactive London about their wholly-owned subsidiary AxisBiotix Limited which is getting ready for their food supplement consumer study. The study, which will accept around 200 applicants, the participants will be asked to take a...

5 days, 4 hours ago

2 min read